You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,920,800


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,920,800
Title:Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
Abstract: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.
Inventor(s): Keer; Harold (Redwood City, CA)
Assignee: Five Prime Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/913,292
Patent Claims:1. A method of treating a human having a cancer, the method comprising: reducing the fibroblast growth factor-2 (FGF-2) plasma concentration of the human below 4 pg/ml for at least one week by administering to the human a soluble fibroblast growth factor receptor 1 (FGFR1) fusion protein at a dose of at least about 2 mg/kg body weight, wherein the soluble FGFR1 fusion protein comprises an FGFR1 extracellular domain linked to a Fc polypeptide, and wherein the human has a FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein; and wherein the method further comprises administering at least one chemotherapeutic agent.

2. The method of claim 1, wherein at least one chemotherapeutic agent is selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, etoposide, irinotecan, topotecan, and an aromatase inhibitor.

3. The method of claim 1, wherein at least one chemotherapeutic agent is selected from docetaxel, paclitaxel, and carboplatin.

4. The method of claim 1, wherein the method comprises reducing the FGF-2 plasma concentration of the human below 4 pg/ml for at least two weeks.

5. The method of claim 1, wherein the method comprises reducing the FGF-2 plasma concentration of the human below 4 pg/ml as determined by an electrochemiluminescence assay, and wherein the human has FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein as determined by an electrochemiluminescence assay, wherein the electrochemiluminescence assay utilizes an anti-FGF-2 antibody as the primary antibody and a ruthenium metal chelate anti-human growth factor antibody blend as the secondary antibody.

6. The method of claim 1, wherein the FGFR1 extracellular domain comprises the amino acid sequence of SEQ ID NO:5.

7. The method of claim 1, wherein the soluble FGFR1 fusion protein comprises the amino acid sequence of SEQ ID NO:8.

8. The method of claim 1, wherein the soluble FGFR1 fusion protein is administered at a dose of about 2 mg/kg body weight to about 20 mg/kg body weight.

9. The method of claim 8, wherein the soluble FGFR1 fusion protein is administered at a dose of about 8 mg/kg body weight to about 16 mg/kg body weight.

10. The method of claim 9, wherein the soluble FGFR1 fusion protein is administered at a dose of about 8 mg/kg body weight.

11. The method of claim 9, wherein the soluble FGFR1 fusion protein is administered at a dose of about 16 mg/kg body weight.

12. The method of claim 1, wherein the cancer is prostate cancer, breast cancer, colorectal cancer, lung cancer, endometrial cancer, head and neck cancer, laryngeal cancer, liver cancer, renal cancer, glioblastoma, or pancreatic cancer.

13. The method of claim 1, wherein the human has an FGF-2 plasma concentration of at least 10 pg/ml prior to the administration of the soluble FGFR1 fusion protein, wherein the FGF-2 plasma concentration is determined according to an electrochemiluminescence assay, which utilizes an anti-FGF-2 antibody as the primary antibody and a ruthenium metal chelate anti-human growth factor antibody blend as the secondary antibody.

14. The method of claim 1, wherein the soluble FGFR1 fusion protein is administered by intravenous infusion.

15. The method of claim 14, in which the intravenous infusion is over a period of 30 minutes.

16. The method of claim 12, wherein the cancer is prostate cancer, breast cancer, colorectal cancer, lung cancer, endometrial cancer, head and neck cancer, laryngeal cancer, liver cancer, renal cancer, glioblastoma, or pancreatic cancer.

17. A method of treating a human having a cancer, the method comprising: reducing the fibroblast growth factor-2 (FGF-2) plasma concentration of the human below 4 pg/ml for at least one week by administering to the human a soluble fibroblast growth factor receptor 1 (FGFR1) fusion protein at a dose of at least about 2 mg/kg body weight, wherein the soluble FGFR1 fusion protein comprises an FGFR1 extracellular domain linked to a Fc polypeptide, and wherein the human has a FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein; and wherein the method further comprises administering at least one VEGF antagonist.

18. The method of claim 17, wherein the VEGF antagonist is selected from a VEGF antibody and a VEGF trap.

19. The method of claim 18, wherein the VEGF antagonist is a VEGF antibody.

20. The method of claim 19, wherein the VEGF antibody is bevacizumab.

21. The method of claim 18, wherein the VEGF antagonist is a VEGF trap.

22. The method of claim 21, wherein the VEGF trap is aflibercept.

23. The method of claim 17, wherein the VEGF antagonist is selected from sorafenib and sunitinib.

24. The method of claim 17, wherein the method comprises reducing the FGF-2 plasma concentration of the human below 4 pg/ml for at least two weeks.

25. The method of claim 17, wherein the method comprises reducing the FGF-2 plasma concentration of the human below 4 pg/ml as determined by an electrochemiluminescence assay, and wherein the human has FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein as determined by an electrochemiluminescence assay, wherein the electrochemiluminescence assay utilizes an anti-FGF-2 antibody as the primary antibody and a ruthenium metal chelate anti-human growth factor antibody blend as the secondary antibody.

26. The method of claim 17, wherein the FGFR1 extracellular domain comprises the amino acid sequence of SEQ ID NO:5.

27. The method of claim 17, wherein the soluble FGFR1 fusion protein comprises the amino acid sequence of SEQ ID NO:8.

28. The method of claim 17, wherein the soluble FGFR1 fusion protein is administered at a dose of about 2 mg/kg body weight to about 20 mg/kg body weight.

29. The method of claim 17, wherein the soluble FGFR1 fusion protein is administered at a dose of about 8 mg/kg body weight to about 16 mg/kg body weight.

30. The method of claim 29, wherein the soluble FGFR1 fusion protein is administered at a dose of about 8 mg/kg body weight.

31. The method of claim 29, wherein the soluble FGFR1 fusion protein is administered at a dose of about 16 mg/kg body weight.

Details for Patent 8,920,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2030-11-15
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 11/18/2011 ⤷  Try a Trial 2030-11-15
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 08/16/2018 ⤷  Try a Trial 2030-11-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.